MehmetF GokhamHepgurMD

Oncology • Deerfield Beach, FL

Gastrointestinal Cancer, Genitourinary Oncology, Hematologic Oncology

Attending Hematologist/Oncologist

Join to view full profile

Dr. Hepgur is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hepgur's full profile

Already have an account?

Office
201 E Sample Rd
Deerfield Beach, FL 33064
Phone+1 954-786-6460

Fax+1 954-786-7304

Summary

Mehmet Hepgur, MD, is an experienced oncologist based in Deerfield Beach, FL. He has several subspecialties, including Gastrointestinal Cancer, Genitourinary Oncology, and Hematologic Oncology. He completed his fellowship in Medical Oncology at the University of Southern California/LAC+USC Medical Center and is currently an Assistant Professor at Nova Southeastern University and an attending Hematologist/Oncologist at Broward Health Medical Center. Dr. Hepgur has extensive experience with conditions like amyloidosis, prostate cancer, and melanoma, and he has been published in several medical publications. He has been recognized with awards such as the Best Research Presentation Award from USC Keck School of Medicine in 2014 and the Conquer Cancer Foundation Merit Award in 2013.

Education & Training

University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2011 - 2014
University at BuffaloResidency, Internal Medicine, 2008 - 2011
Istanbul University FomClass of 1999

Certifications & Licensure

CA State Medical License 2010 - 2026
FL State Medical License 2014 - 2026
TN State Medical License 2014 - 2019
AL State Medical License 2006 - 2006
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Best Research Presentation Award USC Keck School of Medicine, 2014
Conquer Cancer Foundation Merit Award American Society of Medical Oncology, 2013

Publications & Presentations

PubMed

1 citations
Durable complete remission from castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal.
Tanya B. Dorff, Cy Wilkins, Mehmet Hepgur, David I. Quinn
Clinical Genitourinary Cancer. 2014-04-01
7 citations
Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH/CFHR1-3 and complement factor H 479.
Preeti Chaudhary, Mehmet Hepgur, Sarmen Sarkissian, Richard J.H. Smith, Ilene C. Weitz
Blood Transfusion = Trasfusione Del Sangue. 2014-01-01
17 citations
Tivozanib in the treatment of renal cell carcinoma
Mehmet Hepgur, Sarmad Sadeghi, Tanya B. Dorff, David I. Quinn
Biologics. 2013-06-11

Journal Articles

Evaluation of Skull Thickness and Insertion Torque at the Halo Pin Insertion Areas in the Elderly
Ebraheim N, Hepgur M, The Spine Journal
Solitary Splenic Metastasis from Primary Non Small Cell Carcinoma of the Lung
Hepgur M Noor M DePlato A, International Journal of Hematology and Oncology

Abstracts/Posters

Dynamic changes in biomarkers for immune response to sipuleucel-t (SipT) for metastatic castrate-resistant prostate cancer (mCRPC)
Mehmet Faith Hepgur, Tanya B. Dorff, Jie Cai, Mary Reed, Betty Chan, David I. Quinn;, J Clin Oncol 33, 2015 (suppl 7; abstr 181)
Identification of biological and inflammatory markers for predicting clinical responses to Sipuleucel-T in mCRPC.
Hepgur M, Dorff TB, Cai J, Pinski JK, Reed M, Luther M, Chan M, Quinn DI., ASCO GU Cancers Symposium, 2/2014
Clinical and biological factors for immune response to Sipuleucel-T for metastatic castrate resistant prostate cancer.
Hepgur M, Dorff TB, Cai J, Pinski JK, Reed M, Luther M, Chan M, Quinn DI., ASCO GU Cancers Symposium, 2/2014
Ewings Sarcoma in adults: A retrospective review of dose and tolerability of treatment.
Hepgur M, Hu J., Connective Tissue Society 18th Annual Meeting, 9/2013
Two Year Update on the Evaluation of Patients, Safety, and Efficacy of Sipuleucel-T in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) at an Aca...
Kam EH, Chan BM, Hepgur M, Dorff TB, Quinn DI, HOPA Annual Meeting, 3/2013
Changes in circulating tumor cells (CTC) and markers of inflammation after sipuleucel-T treatment.
Hepgur M, Dorff TB, Cai J, Pinski JK, Reed M, Luther M, Chan M, Quinn DI., J Clin Oncol 31, 2013 (supp, Genitourinary Cancers Symposium, 2/11/2013
Early Complete Donor Lymphoid Chimerism With Fludarabine, Melphalan And Low Dose (400CGy) Total Body Irradiation Reduced Intensity Conditioning
Hepgur M McCarthy P, Biology of Blood and Marrow Transplantation, Orlando
Atypical Presentation Of Vaginal GvHD With Abdominal Pain Crises
Hepgur M Battiwalla M mcCarthy P, Biology of Blood and Marrow Transplantation, Orlando
Join now to see all

Press Mentions

How World Cancer Day Highlights Cancer Prevention and Risk AwarenessFebruary 4th, 2025
Broward Health and Voluntis Launch a New Clinical Evaluation Program on Digital Therapeutics for Metastatic Breast CancerMarch 18th, 2021